Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Mar 16;10:4748. doi: 10.1038/s41598-020-61727-3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Contribution of PGRMC1 to the resistance to erlotinib in lung adenocarcinomas cancer. (a) Immunoblotting of PGRMC1 in PC9 and PC9/ER cells. The upper panel shows a representative blot. The lower panel shows means ± SD (n = 3); *P < 0.05 vs. PC9 (two-tailed Student t-test). (b) Immunoblotting analysis of the efficiency of transfection of PC9 and PC9/ER cells with PGRMC1 siRNA (siPGRMC1). NC, negative control. The results shown are representative of 2 independent experiments. (c) WST-8 assay of the effects of various concentrations of erlotinib on cell viability of PGRMC1 siRNA–treated PC9 and PC9/ER cells. Data are means ± SD (n = 3); **P < 0.01, *P < 0.05 vs. PC9 (negative control); ^†P < 0.05, ^††P < 0.01 vs. PC9/ER (negative control) (Two-Way ANOVA followed by Tukey correction). NC, negative control. (d) Immunoblotting analysis of the efficiency of transfection of PC9 cells with a PGRMC1-expressing plasmid. (e) WST-8 assay of the effects of various concentrations of erlotinib on PC9 cells transfected with empty vector or pCMV3-PGRMC1. Data are means ± SD (n = 3); **P < 0.01 vs. PC9 with empty vector (Two-Way ANOVA followed by Bonferroni correction).